Immunomodulatory role of mesenchymal stem cell therapy in liver fibrosis.
Immunomodulatory role of mesenchymal stem cell therapy in liver fibrosis.
复制标题
DOI：
10.3389/fimmu.2022.1096402
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
肝纤维化是一种由肝细胞损伤引起的纤维化和炎症过程，其特征是肝脏结构扭曲和由此导致的肝功能丧失。除肝移植外，目前尚无有效的治疗晚期纤维化的方法，但其受限于昂贵的费用、免疫排斥反应和术后并发症。近年来，随着再生医学的发展，间充质干细胞移植已成为治疗肝纤维化最有前途的方法。MSC抗肝纤维化的机制包括肝细胞分化、旁分泌和免疫调节，其中免疫调节起核心作用。本文综述了参与肝纤维化的免疫细胞、间充质干细胞的免疫调节特性以及以间充质干细胞为基础的抗肝纤维化策略的免疫调节机制。同时，我们也讨论了当前的挑战和未来的发展方向。
Liver fibrosis is a fibrogenic and inflammatory process that results from hepatocyte injury and is characterized by hepatic architectural distortion and resultant loss of liver function. There is no effective treatment for advanced fibrosis other than liver transplantation, but it is limited by expensive costs, immune rejection, and postoperative complications. With the development of regenerative medicine in recent years, mesenchymal stem cell (MSCs) transplantation has become the most promising treatment for liver fibrosis. The underlying mechanisms of MSC anti-fibrotic effects include hepatocyte differentiation, paracrine, and immunomodulation, with immunomodulation playing a central role. This review discusses the immune cells involved in liver fibrosis, the immunomodulatory properties of MSCs, and the immunomodulation mechanisms of MSC-based strategies to attenuate liver fibrosis. Meanwhile, we discuss the current challenges and future directions as well.